Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527701 | 1.00 | TSHR (0.56) | TSHRNR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL271429 | 1.00 | TSHR (0.56) | TSHRNR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL29249586 | 0.89 | TSHR (0.50) | TSHRNR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL12021385 | 0.89 | TSHR (0.50) | TSHRNR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL30591044 | 0.89 | TSHR (0.50) | TSHRNR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL24684727 | 0.89 | TSHR (0.50) | TSHRNR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL29942260 | 0.89 | TSHR (0.50) | TSHRNR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL24685136 | 0.89 | TSHR (0.50) | TSHRNR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL24779803 | 0.89 | TSHR (0.50) | TSHRNR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL29942781 | 0.89 | TSHR (0.50) | TSHRNR1H2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096149-B | Process for the preparation of beta-arylamines | 富兰克科技（深圳）股份有限公司 | 2021-02-26 | — | — | CN | claimed |
| EP-4396305-B1 | SYNTHESIS OF MDMA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA ISOMERS | EMPATHBIO INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12492178-B2 | Stable polymorph of R-MDMA HCl | EMPATHBIO, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4615828-A2 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EmpathBio, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250152553-A1 | CARBAMOTHIOATE, AND CARBAMODITHIOATE DERIVATIVES OF MDMA, MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA AND MDA ISOMERS | EMPATHBIO, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2025096895-A1 | CARBAMOTHIOATE, AND CARBAMODITHIOATE DERIVATIVES OF MDMA, MDA OR ITS OPTICALLY ACTIVE ( R)- OR ( S)-MDMA AND MDA ISOMERS | EMPATHBIO, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | disclosed |
| CN-119775163-A | (S) -3-aminobutyric acid hydrochloride compound and preparation method thereof | 诚达药业股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20250051276-A1 | ARYLOXY PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| CN-118834153-A | 5-Substituted indoline chiral amine, preparation method thereof and application thereof in preparation of silodosin | 浙江大学 | 2024-10-25 | — | — | CN | disclosed |
| CN-109096149-A | The preparation method of β arylamine | 富兰克科技（深圳）股份有限公司 | 2018-12-28 | — | — | CN | disclosed |
| US-8338467-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058293-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2274306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009114566-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | WO | disclosed |
| US-7045545-B1 | Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists | ELI LILLY AND COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| EP-1149085-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000044737-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051276-A1 | ARYLOXY PSYCHOPLASTOGENS AND USES THEREOF | GRIN2A, GRIN2C, GAP43 | TSHR 2703/4885NR1H2 190/4885CHRM2 716/4885 |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | PNMT, SLC6A3, HTR3B | TSHR 1582/4885NR1H2 1382/4885CHRM2 464/4885 |
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | TSHR 418/4885NR1H2 107/4885CHRM2 98/4885 |
| US-20250152553-A1 | CARBAMOTHIOATE, AND CARBAMODITHIOATE DERIVATIVES OF MDMA, MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA AND MDA ISOMERS | DDT, PNMT, CES2 | TSHR 1734/4885NR1H2 3086/4885CHRM2 557/4885 |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | TSHR 418/4885NR1H2 107/4885CHRM2 98/4885 |
| US-12492178-B2 | Stable polymorph of R-MDMA HCl | HTR3A, OPRM1, HTR3B | TSHR 3964/4885NR1H2 175/4885CHRM2 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.